BRPI1007483A2 - biomarcadores associados com nefropatia. - Google Patents

biomarcadores associados com nefropatia.

Info

Publication number
BRPI1007483A2
BRPI1007483A2 BRPI1007483A BRPI1007483A BRPI1007483A2 BR PI1007483 A2 BRPI1007483 A2 BR PI1007483A2 BR PI1007483 A BRPI1007483 A BR PI1007483A BR PI1007483 A BRPI1007483 A BR PI1007483A BR PI1007483 A2 BRPI1007483 A2 BR PI1007483A2
Authority
BR
Brazil
Prior art keywords
nephropathy
biomarkers associated
biomarkers
Prior art date
Application number
BRPI1007483A
Other languages
English (en)
Inventor
Ching-Fang Lu
Chwei-Shiun Yang
Mary Ya-Ping Yeh
Tsai-Wei Hsu
Tzu-Ling Tseng
Wei-Ya Lin
Yi-Ting Chen
Original Assignee
Ind Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Tech Res Inst filed Critical Ind Tech Res Inst
Publication of BRPI1007483A2 publication Critical patent/BRPI1007483A2/pt
Publication of BRPI1007483B1 publication Critical patent/BRPI1007483B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
BRPI1007483-0A 2009-01-28 2010-01-27 Método de diagnóstico de nefropatia in vitro, método in vitro para o monitoramento de progresso de nefropatia, método in vitro para o monitoramento da eficácia de um tratamento de nefropatia, método in vitro de avaliação de toxicidade renal de um agente e kit para diagnóstico de nefropatia BRPI1007483B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14778509P 2009-01-28 2009-01-28
US61/147,785 2009-01-28
PCT/CA2010/000096 WO2010085878A1 (en) 2009-01-28 2010-01-27 Biomarkers associated with nephropathy

Publications (2)

Publication Number Publication Date
BRPI1007483A2 true BRPI1007483A2 (pt) 2016-02-16
BRPI1007483B1 BRPI1007483B1 (pt) 2021-11-30

Family

ID=42395075

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007483-0A BRPI1007483B1 (pt) 2009-01-28 2010-01-27 Método de diagnóstico de nefropatia in vitro, método in vitro para o monitoramento de progresso de nefropatia, método in vitro para o monitoramento da eficácia de um tratamento de nefropatia, método in vitro de avaliação de toxicidade renal de um agente e kit para diagnóstico de nefropatia

Country Status (12)

Country Link
US (5) US20100209948A1 (pt)
EP (1) EP2391653B8 (pt)
JP (1) JP5524241B2 (pt)
CN (1) CN102300875B (pt)
BR (1) BRPI1007483B1 (pt)
CA (1) CA2748852C (pt)
DK (1) DK2391653T3 (pt)
ES (1) ES2530574T3 (pt)
MX (1) MX2011007810A (pt)
PT (1) PT2391653E (pt)
TW (1) TWI397687B (pt)
WO (1) WO2010085878A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085879A1 (en) * 2009-01-28 2010-08-05 Industrial Technology Research Institute Urine and serum biomarkers associated with diabetic nephropathy
KR101732706B1 (ko) * 2015-06-05 2017-05-04 압타바이오 주식회사 신증 진단용 마커로서의 sh3yl1의 용도
ES2946541T3 (es) * 2016-06-10 2023-07-20 Univ Warszawski Medyczny Métodos de diagnóstico y seguimiento utilizando proteínas en orina como marcadores en la nefropatía por IgA
US20210364529A1 (en) * 2019-01-17 2021-11-25 National University Corporation Okayama University Method and kit for determining possibility of onset of iga nephropathy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4640909A (en) * 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
EE04817B1 (et) * 1996-05-24 2007-04-16 Biogen, Incorporated Kudede regeneratsiooni modulaatorid
CA2273196C (en) * 1996-12-06 2012-02-07 Schering Corporation Isolated mammalian monocyte cell genes; related reagents
US6140076A (en) * 1996-12-06 2000-10-31 Schering Corporation Ig superfamily `dlair` receptors expressed in monocytes
US20040029175A1 (en) * 1998-12-21 2004-02-12 Comper Wayne D. Method for kidney disease detection
IL143892A0 (en) * 1998-12-21 2002-04-21 Univ Monash Kidney disease detection and treatment
AUPP784398A0 (en) * 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
ATE528392T1 (de) * 1999-06-28 2011-10-15 Yusuke Nakamura Neues protein und dessen dns
ES2312780T3 (es) * 2002-05-13 2009-03-01 Arexis Ab Afecciones autoinmunes y deficiencias de oxidasa nadph.
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
DK2360475T3 (da) * 2003-03-27 2020-01-06 Childrens Hospital Med Ct Fremgangsmåde og kit til detektion af tidlig indtræden af renal tubulær celleskade
BRPI0519096A2 (pt) * 2004-12-15 2008-12-23 Beth Israel Hospital Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez
US20060257481A1 (en) * 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
WO2007102736A2 (en) * 2006-03-08 2007-09-13 Universitair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen.
US7662578B2 (en) * 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
WO2008021431A2 (en) * 2006-08-14 2008-02-21 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
WO2008063783A2 (en) * 2006-10-13 2008-05-29 Metabolon, Inc. Biomarkers related to metabolic age and methods using the same
US20080187944A1 (en) * 2007-01-31 2008-08-07 Appa Rao Allam Butyrylcholinesterase as a marker of low-grade systemic inflammation
CN101680903A (zh) * 2007-03-21 2010-03-24 比奥波托诊断股份公司 肾损伤的诊断试验
EP2153234A2 (en) * 2007-05-11 2010-02-17 The Institutes for Pharmaceutical Discovery, LLC Methods for early diagnosis of kidney disease
WO2010085879A1 (en) * 2009-01-28 2010-08-05 Industrial Technology Research Institute Urine and serum biomarkers associated with diabetic nephropathy

Also Published As

Publication number Publication date
US20130266976A1 (en) 2013-10-10
US20100209948A1 (en) 2010-08-19
CA2748852A1 (en) 2010-08-05
TWI397687B (zh) 2013-06-01
US20110086372A1 (en) 2011-04-14
TW201033615A (en) 2010-09-16
PT2391653E (pt) 2015-02-13
EP2391653A4 (en) 2012-06-27
EP2391653B8 (en) 2015-09-30
BRPI1007483B1 (pt) 2021-11-30
US20110081667A1 (en) 2011-04-07
US9442120B2 (en) 2016-09-13
WO2010085878A1 (en) 2010-08-05
JP2012516430A (ja) 2012-07-19
DK2391653T3 (en) 2015-02-09
US20110081668A1 (en) 2011-04-07
JP5524241B2 (ja) 2014-06-18
CN102300875B (zh) 2014-07-16
MX2011007810A (es) 2011-09-30
CN102300875A (zh) 2011-12-28
EP2391653A1 (en) 2011-12-07
US8470547B2 (en) 2013-06-25
CA2748852C (en) 2019-05-28
EP2391653B1 (en) 2014-12-31
ES2530574T3 (es) 2015-03-03

Similar Documents

Publication Publication Date Title
BRPI1006166A2 (pt) gestos padrão.
BRPI1010653A2 (pt) refrigerador.
BRPI1011275A2 (pt) refrigerador.
BRPI1007047A2 (pt) Biorrefino irganosolv de cana-de-açúcar inteira.
BRPI1010301A2 (pt) composição.
EP2398939A4 (en) MICROARRAY WITH MICRO CHANNELS
BRPI0920069A2 (pt) biomarcadores
DK2430035T3 (da) Uracylspipooxetannukleosider
EP2265642A4 (en) BIOMARKERS
BRPI1009811A2 (pt) transmissão.
FR2947376B1 (fr) Sectionneur.
BRPI0924633A2 (pt) refrigerador.
IT1396487B1 (it) Convogliatore.
BR112012001062A2 (pt) laminados com microtextura.
DK2442870T3 (da) Pyrazinooxazepin-derivater.
EP2263086A4 (en) BIOMARKERS
IT1394665B1 (it) Granitore.
BRPI1011794A2 (pt) compartimento.
BR112012002612A2 (pt) calha.
EP2265641A4 (en) BIOMARKERS
EP2391653A4 (en) BIOMARKERS ASSOCIATED WITH NEPHROPATHY
IT1396642B1 (it) Statore.
FR2943510B1 (fr) Ombrelle.
BR112012000911A2 (pt) biomarcador.
ES1073526Y (es) Almohada.

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: BIO PREVENTIVE MEDICINE CORPORATION (TW)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.